264 related articles for article (PubMed ID: 10883671)
1. Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis.
Nnane IP; Long BJ; Ling YZ; Grigoryev DN; Brodie AM
Br J Cancer; 2000 Jul; 83(1):74-82. PubMed ID: 10883671
[TBL] [Abstract][Full Text] [Related]
2. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
3. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
4. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds.
Nnane IP; Kato K; Liu Y; Long BJ; Lu Q; Wang X; Ling YZ; Brodie A
Endocrinology; 1999 Jun; 140(6):2891-7. PubMed ID: 10342882
[TBL] [Abstract][Full Text] [Related]
6. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo.
Grigoryev DN; Long BJ; Nnane IP; Njar VC; Liu Y; Brodie AM
Br J Cancer; 1999 Oct; 81(4):622-30. PubMed ID: 10574247
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic profile of 3beta-hydroxy-17-(1H-1,2,3-triazol-1-yl)androsta-5,16-diene (VN/87-1), a potent androgen synthesis inhibitor, in mice.
Nnane IP; Njar VC; Brodie AA
J Steroid Biochem Mol Biol; 2001 Sep; 78(3):241-6. PubMed ID: 11595504
[TBL] [Abstract][Full Text] [Related]
9. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
[TBL] [Abstract][Full Text] [Related]
10. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
[TBL] [Abstract][Full Text] [Related]
11. Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.
Handratta VD; Jelovac D; Long BJ; Kataria R; Nnane IP; Njar VC; Brodie AM
J Steroid Biochem Mol Biol; 2004 Oct; 92(3):155-65. PubMed ID: 15555909
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of androgen synthesis by 22-hydroximino-23,24-bisnor-4-cholen-3-one.
Li J; Li Y; Son C; Brodie AM
Prostate; 1995 Mar; 26(3):140-50. PubMed ID: 7534917
[TBL] [Abstract][Full Text] [Related]
13. Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo.
Nnane IP; Njar VC; Liu Y; Lu Q; Brodie AM
J Steroid Biochem Mol Biol; 1999 Dec; 71(3-4):145-52. PubMed ID: 10659703
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
Vasaitis T; Belosay A; Schayowitz A; Khandelwal A; Chopra P; Gediya LK; Guo Z; Fang HB; Njar VC; Brodie AM
Mol Cancer Ther; 2008 Aug; 7(8):2348-57. PubMed ID: 18723482
[TBL] [Abstract][Full Text] [Related]
15. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
Rehman Y; Rosenberg JE
Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
[TBL] [Abstract][Full Text] [Related]
17. 17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P450(17 alpha).
Ling YZ; Li JS; Liu Y; Kato K; Klus GT; Brodie A
J Med Chem; 1997 Sep; 40(20):3297-304. PubMed ID: 9379450
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer: The androgen receptor remains front and centre.
Saylor PJ
Nat Rev Clin Oncol; 2013 Mar; 10(3):126-8. PubMed ID: 23381000
[No Abstract] [Full Text] [Related]
19. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.
Locke JA; Guns ES; Lehman ML; Ettinger S; Zoubeidi A; Lubik A; Margiotti K; Fazli L; Adomat H; Wasan KM; Gleave ME; Nelson CC
Prostate; 2010 Feb; 70(3):239-51. PubMed ID: 19790237
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
Bedoya DJ; Mitsiades N
Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
[No Abstract] [Full Text] [Related]
[Next] [New Search]